Clinical Trial Update: Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on a personalized neoantigen cancer vaccine with radiotherapy and pembrolizumab for newly diagnosed glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Personalized Neoantigen Cancer Vaccine

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING